SG3 Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

SG3 Management’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-22,500	Closed	-$220K	–	1447
2021 Q4	$220K	Buy	22,500 +16,500	+275%	+$310K	﹤0.01%	792
2021 Q3	$204K	Buy	+6,000	New	+$191K	0.01%	774
2021 Q2	–	Sell	-13,500	Closed	-$605K	–	1413
2021 Q1	$605K	Buy	+13,500	New	+$629K	0.02%	724

Other funds holding DCPH

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

SG3 Management's DCPH Position: Q1 2022 in Review

SG3 Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q1 2022, closing a stake of 22,500 shares — an estimated $220K sold.

SG3 Management first reported a position in DCPH in Q1 2021 and held it in 3 quarters. The position peaked at $605K in Q1 2021. 123 funds tracked by Wall St. Rank hold DCPH as of Q1 2022.

SG3 Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 22,500 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $220K.
SG3 Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
SG3 Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $605K in Q1 2021.
123 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.